70 results about "Cardiac Stem Cell" patented technology

Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration cytokines are disclosed and claimed. Methods and compositions for the development of large arteries and vessels are also disclosed and claimed. The present application also discloses and claims methods and media for the growth, expansion, and activation of human cardiac stem cells.

Compositions of isolated adult organ stem cells, including hematopoietic stem cells, cardiac stem cells, and kidney stem cells, are disclosed. In particular, the present invention provides c-kit positive, lineage negative adult stem cells that can be isolated from adult organ tissue. Such stem cells are capable of generating all the cell lineages of the organ tissue from which they were isolated. Methods for repairing damaged organ tissue with the isolated organ stem cells are also disclosed.

The invention describes the isolation and methods of use of a non-senescent pool of adult cardiac stem cells. In particular, a subset of adult cardiac stem cells with superior regenerative capacity is disclosed. Such cells were found to have immortal DNA. Compositions comprising the non-senescent stem cells are also described. In addition, the present invention provides methods for repairing aged myocardium or damaged myocardium using the isolated non-senescent adult cardiac stem cells.

Method for the isolation, expansion and preservation of cardiac stem cells from human or animal tissue biopsy samples to be employed in cell transplantation and functional repair of the myocardium or other organs. Cells may also be used in gene therapy for treating genetic cardiomyopathies, for treating ischemic heart diseases and for setting in vitro models to study drugs.

Dedifferentiation is a mechanism whereby specialized cells regain properties of their ancestors, including, in the extreme, stemness. We found that highly-purified cardiomyocytes isolated from adult mammalian hearts dedifferentiated rapidly when cultured in mitogen-rich medium. Such myocytes reentered the cell cycle and proliferated, expressing stem cell surface markers such as c-kit and early cardiac transcription factors including GATA and NKx2.5. These myocyte-derived cells (MDC) were capable of re-differentiating into myocytes and endothelial cells. Contrary to prevailing dogma, cardiomyocyte dedifferentiation yields proliferative cells expressing stem cell markers and capable of multilineage differentiation. Cardiomyocyte dedifferentiation is a potential source of endogenous stem cells in the adult heart.

A biopsy forceps (1) comprises a flexible pipe (2) which can be remotely controlled. Two handles (6 and 7) which are connected to the near end of the pipe are used for operating a pair of clamps (4 and 5) that are connected to the far end of the pipe. An independent control handle (8) comprises a rotatable knob (16). The knob rotates in the reverse direction to facilitate the bending of the pipe in the second direction. A control knob can be connected to the far end of the pipe through the operating lines (42 and 43) that moves in the cavities (44 and 45) of the pipe in company with the rotation of the knob. The clamps (or other control component) at the far end of the pipe are replaceable (80A and 80B).

The present invention relates to compositions and methods for inducing cardiomyogenesis in mammalian cells, particularly embryonic stem cells in vitro and in vivo.

The invention discloses a method for separating heart stem cells from brown fat and splitting cardioblast. The method comprises the following steps: (1) preparing digestive juice: dissolving callagenase, dispase II and pancreatin in the mass ratio of 1:1:0.5-1 in a serum-free culture medium; (2) digesting the brown fat tissue with a digestion bottle added with glass beads and rotors, and then centrifugally collecting the cells; and (3) cultivating the progenitor heart stem cells and splitting the cardioblast. By adopting the combined digestive enzyme liquid and a special digestion method for cell separation, the separation method remarkable improves the yield of cells and the content of heart stem cells compared with the existing separation method, and remarkably improves the yield of the heart stem cells by verifying the expression rate of CD133 and the capability of the cardioblast. By using the method, the yield of the obtained heart stem cells is high, the operation is simple, the implementability is strong and the manual operation is reduced.

Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.

The invention relates to a biologic patch material and concretely relates to a biologic patch material for cardiac repair. The biologic patch material comprises (i) at least two porous structural layers that are compounded together, wherein the porous structural layer comprises a first structural layer for preventing repairing cell loss and a second structural layer for loading (or accommodating) cardiac repairing cells and the repairing cells are selected from cardiac stem cells, cardiac progenitor (precursor) cells or their composition (derived from embryonic stem cells, induced pluripotent stem cells, heart tissue stem cells, bone marrow and peripheral blood), and (ii) repairing cells loaded on the second structural layer, wherein at least a part of or all the repairing cells are located in gaps of the second structural layer. The biologic patch material can load growing of repairing cells and has very good biocompatibility and mechanical strength.

The invention discloses a stem cell preparation for treating ischemic cardiomyopathy and a preparation method of the stem cell preparation. The preparation consists of mesenchymal stem cells, cardiac stem cells and vascular endothelial stem cells, and a solvent is platelet-rich plasma lysate of a patient. The stem cells express a corresponding specific identifier and do not express a corresponding non-specific identifier at the same time. The preparation method comprises the following steps: (1), preparing mesenchymal stem cells between a placenta and an umbilical cord; (2), applying different induction culture systems to induce the mesenchymal stem cells in the step (1) to be cardiac stem cells and vascular endothelial stem cells; (3), preparing the solvent which is the platelet-rich plasma lysate; and (4), uniformly mixing and preparing the stem cell preparation. The stem cell preparation disclosed by the invention is rich in resource, easy to prepare, convenient to collect, and free of pain while being applied; moreover, the stem cell preparation is low in immunological rejection after being transplanted. The stem cell preparation comprises a plurality of stem cells, so that advantages of combined effect of a plurality of cells can be brought into play; the solvent is easily available, and can directly act on a patient; besides, transplantation effect is enhanced.

The invention provides a freezing solution for cardiac stem cell. The stem cell comprises a DMEM basic medium, fetal bovine serum, vitamin E, trehalose and hydroxyethyl starch. The dose of fetal bovine serum is 0.8-2.0% of the weight of the DMEM basic medium. The density of the vitamin E is 18-25 micro mol/Ls. The density of the trehalose is 0.1-0.3 mol/L. The dose of the hydroxyethyl starch is 10-13% of the weight of the DMEM basic medium. A freezing method using the freezing solution is also provided. The freezing solution has no toxic protective agent such as DMSO, and has utterly good cell recovery rate as high as 94.55% for the freezing of cardiac stem cell.